Souhaitez-vous accéder aux communiqués récents ?

R1 Therapeutics launches with oversubscribed $77.5 million Series A financing to advance first-in-class treatment for hyperphosphatemia.

Phase 2 Study Demonstrated 73% clinical Clearance in the 200-µg Arm suggests that ~3 out of 4 treated lesions may allow patients to avoid immediate surgical intervention. PHILADELPHIA, March 16,...

George Medicines signs exclusive licensing agreement with Ahngook Pharmaceutical to commercialize GMRx2 in Korea GMRx2 is an innovative single pill combination of three medicines designed to deliver...

Tokyo, Japan and Cambridge, UK, 5 March 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that Centessa Pharmaceuticals has achieved an additional early development...

SHENZHEN, CHINA, March 05, 2026 (GLOBE NEWSWIRE) -- China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that self-developed innovative drug INHBE-targeting small...

Company announces manufacturing readiness and financing extension ahead of first-in-human clinical study London, United Kingdom, March 5, 2026, Swarm Oncology Ltd. (“Swarm Oncology” or “Swarm” or...

Daridorexant is a dual orexin receptor antagonist being developed in South Korea by Nxera for the treatment of adult patients with insomnia and is approved and marketed in Japan as QUVIVIQ®Phase 3...

London, UK – 3 March, 2026 – Quell Therapeutics Ltd (“Quell”), a leader in developing engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system, today...

Biologic Innovation to Drive Global Ophthalmic Drugs Market Growth at 7.9% CAGR Through 2036, supported by anti-VEGF therapies and AI-enabled imaging.

GMRx2 is an innovative single pill combination of three medicines designed to deliver the blood pressure-lowering benefits of triple combination therapy early in the treatment pathway, supported by an...